LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

On November 3, 2025, uniQure announced a regulatory update regarding its investigational gene therapy for Huntington’s disease, AMT-130 ... advancing transformative therapies for patients with severe ...

SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...

Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment. Experts from University College London (UCL) said the finding could “change ...

Qure's stock narrative has been recently revised, with the Fair Value Estimate remaining constant at $75.09 per share while the discount rate ticked up marginally from 6.70% to 6.76%. This comes amid ...

MRI of a brain with Huntington's Disease. Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and devastating neurodegenerative disorder, at his clinic at the University ...

Our weekly roundup of the latest science in the news, as well as a few fascinating articles to keep you entertained over the ...